Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Xeris Biopharma excels in Q1 with strong revenue growth and strategic partnerships

Xeris Biopharma delivered a strong Q1 performance with significant revenue growth, solid product sales, and a healthy cash position, supported by effective financial management.
While facing challenges from potential generic competition and market dynamics, the company's strategic strengths, partnerships, and innovation drive its growth trajectory.
Opportunities in expanding product lines, leveraging partnerships, and investing in R&D position Xeris for continued success and market leadership in the pharmaceutical sector.
Maintaining a balance between addressing challenges, capitalizing on opportunities, and sustaining growth momentum will be key for Xeris Biopharma's future success.

Xeris Biopharma reports record revenue, eyes growth amid challenges

Xeris Biopharma delivered robust Q2 performance, driven by strong revenue growth and key product successes.
While facing challenges like screen failures and patent appeals, the company remains focused on growth opportunities and innovation.
With a solid financial outlook, strategic partnerships, and product advancements, Xeris is poised for continued success and market expansion.

Xeris Biopharma excels in Q3, eyes growth through innovation

Xeris Biopharma delivered a strong Q3 performance with notable revenue growth and a focus on improving cash flow and operational efficiency.
The company's emphasis on innovation, market expansion through subcutaneous drug administration, and management's confidence are key strengths.
Challenges lie in a competitive market landscape and managing investor expectations without providing 2024 financial guidance.
Opportunities include acquisitions, market expansion through innovative drug administration, and attracting institutional investment through improved financial performance.

Xeris Biopharma excels in 2023, eyes sustained growth in 2024

Xeris Biopharma's strong financial performance in 2023, driven by key products and strategic initiatives, positions the company for continued growth.
While facing challenges such as generic competition and market expectations, Xeris remains focused on innovation and market expansion.
Opportunities in revenue growth, market expansion benefits, and patient base increase offer promising prospects for Xeris in 2024.
With a solid foundation of financial prudence, innovation, and growth strategies, Xeris is poised to maintain momentum and drive success in the upcoming year.

Xeris Biopharma reports robust Q1 growth and eyes healthcare partnerships

Xeris Biopharma's Q1 2024 showcased strong financial performance, with revenue growth and strategic collaborations driving optimism for the future. Despite challenges like the cybersecurity breach, the company remains focused on innovation and partnerships to address healthcare needs and reduce hospitalizations.

Xeris Biopharma achieves record revenue, eyes growth amid challenges

Xeris Biopharma's Q3 performance reflects robust revenue growth, strategic focus, and product strength, positioning the company for sustained success.
While challenges like maintaining margins and managing expenses persist, opportunities in communication, partnerships, and new product development offer avenues for future growth.
Investors can be optimistic about Xeris Biopharma's financial stability, growth prospects, and commitment to transparency, despite potential market challenges ahead.

Xeris Biopharma surpasses revenue targets in 2024, eyes growth opportunities

Xeris Biopharma Holdings (XERS) delivered strong financial performance in 2024, exceeding revenue guidance and demonstrating growth across key products. While facing challenges in sustaining momentum and meeting ambitious revenue targets, XERS remains well-positioned for growth with a focus on product development and stakeholder engagement. The company's successful commercial strategies, progress in R&D, and commitment to financial discipline provide a solid foundation for future success. By capitalizing on opportunities in product expansion, market growth, and stakeholder communications, XERS can drive continued growth and enhance shareholder value.

Xeris Biopharma reports record-breaking Q1 results and strategic partnerships

Xeris Biopharma delivered exceptional Q1 2025 results, marked by robust revenue growth and strategic advancements in product commercialization and partnerships. The company's focus on innovation, market expansion, and stakeholder communication underscores its commitment to sustainable growth and value creation. While facing challenges in certain product segments, Xeris remains well-positioned to capitalize on opportunities for further market penetration and revenue expansion. Overall, Xeris Biopharma's performance in Q1 2025 reflects a strong foundation for future growth and market leadership in the biopharmaceutical industry.

Xeris Biopharma reports robust Q2 growth, raises revenue guidance

Xeris Biopharma Holdings delivered a strong performance in Q2 2025, driven by revenue growth and positive adjusted EBITDA. The company's focus on key products like Recorlev and strategic investments bodes well for future growth and market expansion. While facing challenges in certain product segments, Xeris remains optimistic about its revenue outlook and continued investment in product development.

Xeris Biopharma reports record Q3 revenue, eyes growth opportunities ahead

Xeris Biopharma's Q3 performance reflects robust revenue growth, operational strength, and improved profitability metrics. Steady progress in key products, commercial expansion, and upcoming trials signal a promising outlook for future growth. While facing challenges in balancing investments and profitability, the company is well-positioned to capitalize on market opportunities. Strategic focus on product development, market expansion, and financial management will be key to sustaining growth momentum.

Xeris Biopharma reports robust Q4 earnings, eyes $1-3B peak revenue

Xeris Biopharma Holdings delivered a strong performance in Q4 2025, achieving financial self-sustainability and significant revenue growth. Key products like Recorlev, Gvoke, and Keveyis demonstrated strength and contributed to the company's positive results. While facing challenges in areas like IP litigation and cost management, Xeris is well-positioned to capitalize on opportunities like XP-8121's Phase III trial. With a focus on strategic priorities and revenue growth, Xeris aims to maintain its success in 2026 and drive further value for shareholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.